Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States
At the set WTP threshold, camr-rivo is a cost-utility treatment strategy compared to sorafenib as a first-line therapy for patients with unresectable or advanced HCC in China but not in the United States.
Authors
- Ruyi Huang (ORCID: https://orcid.org/0000-0002-1004-3835)
- Qiuling Zhao (ORCID: https://orcid.org/0000-0002-4187-3663)
- Long‐Li Lai (ORCID: https://orcid.org/0000-0002-2152-0430)
- Zilin Nian
- Lin Yang (ORCID: https://orcid.org/0000-0002-3509-0523)
- Yimin He
- Yongjian Huang (ORCID: https://orcid.org/0000-0001-9554-6425)
Institutions
- Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3389/fphar.2025.1404389
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64